SEC Form 4 · accession 0001209191-18-064090
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Director
Period of report
Dec 20, 2018
Accepted (ET)
Dec 26, 2018 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 20, 2018 | P | 50,000 | $0.4129 | A | 420,382 | D | |
| Common StockF2 | Dec 21, 2018 | P | 195,000 | $0.4236 | A | 615,382 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents weighted average price for the shares. The shares were purchased at price ranging from $0.4013 to $0.4100 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
- F2Represents weighted average price for the shares. The shares were purchased at price ranging from $0.4048 to $0.4300 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.